Company registration number 09082491 (England and Wales)
PENINSULA HEALTHCARE (UK) LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
PENINSULA HEALTHCARE (UK) LIMITED
COMPANY INFORMATION
Directors
Dr Z Sheikh
Dr R Mahmood
Company number
09082491
Registered office
Parkview House Ground Floor
82 Oxford Road
Uxbridge
UB8 1UX
Auditor
Moore NHC Audit Limited
East Wing
Goffs Oak House
Goffs Lane
Goffs Oak
Hertfordshire
EN7 5GE
PENINSULA HEALTHCARE (UK) LIMITED
CONTENTS
Page
Directors' report
1
Directors' responsibilities statement
2
Independent auditor's report
3 - 6
Consolidated income statement
7
Consolidated statement of comprehensive income
8
Consolidated statement of financial position
9 - 10
Consolidated statement of changes in equity
11
Consolidated statement of cash flows
12
Notes to the consolidated financial statements
13 - 29
Company statement of financial position
30
Company statement of changes in equity
31
Notes to the company financial statements
32 - 34
PENINSULA HEALTHCARE (UK) LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 MARCH 2025
- 1 -
The directors present their annual report and financial statements for the year ended 31 March 2025.
Principal activities
The principal activity of the group continued to be that of the provision of dental practice services.
Results and dividends
The results for the year are set out on page 7.
No ordinary dividends were paid. The directors do not recommend payment of a further dividend.
Directors
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
Dr Z Sheikh
Dr R Mahmood
Statement of disclosure to auditor
Each director in office at the date of approval of this annual report confirms that:
so far as the director is aware, there is no relevant audit information of which the company's auditor is unaware, and
the director has taken all the steps that he / she ought to have taken as a director in order to make himself / herself aware of any relevant audit information and to establish that the company's auditor is aware of that information.
This confirmation is given and should be interpreted in accordance with the provisions of section 418 of the Companies Act 2006.
On behalf of the board
Dr Z Sheikh
Director
20 December 2025
PENINSULA HEALTHCARE (UK) LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 MARCH 2025
- 2 -
The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the group and parent company financial statements in accordance with International Financial Reporting Standards (IFRSs) as adopted by the United Kingdom. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.
In preparing these financial statements, International Accounting Standard 1 requires that directors:
properly select and apply accounting policies;
present information, including accounting policies, in a manner that provides relevant, reliable, comparable and understandable information;
provide additional disclosures when compliance with the specific requirements in IFRSs are insufficient to enable users to understand the impact of particular transactions, other events and conditions on the entity's financial position and financial performance; and
make an assessment of the company's ability to continue as a going concern.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
PENINSULA HEALTHCARE (UK) LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF PENINSULA HEALTHCARE (UK) LIMITED
- 3 -
Opinion
We have audited the financial statements of Peninsula Healthcare (UK) Limited (the ‘parent company’) and its subsidiaries (the ‘group’) for the year ended 31 March 2025 which comprise the consolidated income statement, the consolidated and company statement of financial position, the consolidated and company statement of changes in equity, the consolidated statement of cash flows and the consolidated and company notes to the financial statements, including significant accounting policies.
The financial reporting framework that has been applied in their preparation is applicable law and UK adopted international accounting standards.
In our opinion:
the financial statements give a true and fair view of the state of the group's and of the parent company's affairs as at 31 March 2025 and of the group's loss for the year then ended;
the financial statements have been properly prepared in accordance with UK adopted international accounting standards; and
the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
PENINSULA HEALTHCARE (UK) LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF PENINSULA HEALTHCARE (UK) LIMITED
- 4 -
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of our audit:
the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
the parent company financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent company or to cease operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
PENINSULA HEALTHCARE (UK) LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF PENINSULA HEALTHCARE (UK) LIMITED
- 5 -
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.
As part of an audit in accordance with ISAs (UK), we exercise professional judgment and
maintain professional scepticism throughout the audit. We also:
• Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those
risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the group’s or the parent company’s internal control.
• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
• Conclude on the appropriateness of the directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group’s or the parent company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related
disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of
our auditor’s report. However, future events or conditions may cause the group or the parent company to cease to continue as a going concern.
• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
• Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the group financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
PENINSULA HEALTHCARE (UK) LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF PENINSULA HEALTHCARE (UK) LIMITED
- 6 -
Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud
The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the group.
Our approach was as follows:
We obtained an understanding of the legal and regulatory requirements applicable to the group and considered that the most significant are the Companies Act 2006, UK adopted international accounting standards, and UK taxation legislation
We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required
A further description of our responsibilities is available on the Financial Reporting Council's website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
This report is made solely to the parent company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the parent company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the parent company and the parent company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
Francis Corbishley (Senior Statutory Auditor)
For and on behalf of Moore NHC Audit Limited, Statutory Auditor
Chartered Accountants
East Wing
Goffs Oak House
Goffs Lane
Goffs Oak
Hertfordshire
EN7 5GE
22 December 2025
PENINSULA HEALTHCARE (UK) LIMITED
CONSOLIDATED INCOME STATEMENT
FOR THE YEAR ENDED 31 MARCH 2025
- 7 -
2025
2024
Notes
£
£
Revenue
3
7,401,072
7,890,943
Cost of sales
(4,346,316)
(4,531,229)
Gross profit
3,054,756
3,359,714
Administrative expenses
(3,502,723)
(3,486,815)
Operating loss
4
(447,967)
(127,101)
Finance costs
8
(72,096)
(85,524)
Loss before taxation
(520,063)
(212,625)
Income tax (income)/expense
9
288,793
(6,632)
Loss and total comprehensive income for the year
(231,270)
(219,257)
Profit for the financial year is attributable to:
- Owners of the parent company
(170,138)
(179,846)
- Non-controlling interests
(61,132)
(39,411)
(231,270)
(219,257)
PENINSULA HEALTHCARE (UK) LIMITED
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2025
- 8 -
2025
2024
£
£
Loss for the year
(231,270)
(219,257)
Other comprehensive income:
Total comprehensive income for the year
(231,270)
(219,257)
Total comprehensive income for the year is attributable to:
- Owners of the parent company
(170,138)
(179,846)
- Non-controlling interests
(61,132)
(39,411)
(231,270)
(219,257)
PENINSULA HEALTHCARE (UK) LIMITED
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT
31 MARCH 2025
31 March 2025
- 9 -
2025
2024
Notes
£
£
Non-current assets
Goodwill
10
570,412
570,412
Intangible assets
10
128,720
204,437
Property, plant and equipment
11
2,087,485
2,491,841
2,786,617
3,266,690
Current assets
Inventories
13
32,143
91,638
Trade and other receivables
14
448,502
407,591
Cash and cash equivalents
656,471
118,943
1,137,116
618,172
Current liabilities
Trade and other payables
17
2,565,154
3,229,241
Current tax liabilities
4,609
Lease liabilities
18
215,676
225,550
2,785,439
3,454,791
Net current liabilities
(1,648,323)
(2,836,619)
Non-current liabilities
Trade and other payables
17
-
63,769
Borrowings
16
1,249,850
-
Lease liabilities
18
931,624
1,145,390
Deferred tax liabilities
19
131,212
164,184
2,312,686
1,373,343
Net liabilities
(1,174,392)
(943,272)
Equity
Called up share capital
21
1,000
101
Share premium account
22
999,250
999,999
Retained earnings
(1,827,703)
(1,657,565)
Equity attributable to owners of the parent company
(827,453)
(657,465)
Non-controlling interests
(346,939)
(285,807)
Total equity
(1,174,392)
(943,272)
PENINSULA HEALTHCARE (UK) LIMITED
CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT
31 MARCH 2025
31 March 2025
- 10 -
The financial statements were approved by the board of directors and authorised for issue on 20 December 2025 and are signed on its behalf by:
Dr Z Sheikh
Director
Company registration number 09082491 (England and Wales)
PENINSULA HEALTHCARE (UK) LIMITED
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 11 -
Share capital
Share premium account
Retained earnings
Total
Non-controlling interest
Total
Notes
£
£
£
£
£
£
Balance at 1 April 2023
101
999,999
(1,438,308)
(438,208)
(285,807)
(724,015)
Year ended 31 March 2024:
Loss
-
-
(179,846)
(179,846)
(39,411)
(219,257)
Other comprehensive income:
Amounts attributable to non-controlling interests
-
-
(39,411)
(39,411)
39,411
-
Total comprehensive income
-
-
(219,257)
(219,257)
-
(219,257)
Balance at 31 March 2024
101
999,999
(1,657,565)
(657,465)
(285,807)
(943,272)
Year ended 31 March 2025:
Loss
-
-
(170,138)
(170,138)
(61,132)
(231,270)
Other comprehensive income:
Amounts attributable to non-controlling interests
-
-
(61,132)
(61,132)
61,132
-
Total comprehensive income
-
-
(231,270)
(231,270)
-
(231,270)
Transactions with owners:
Issue of share capital
21
150
(749)
-
(599)
-
(599)
Bonus issue
21
749
-
749
-
749
Other movements
-
-
61,132
61,132
(61,132)
-
Balance at 31 March 2025
1,000
999,250
(1,827,703)
(827,453)
(346,939)
(1,174,392)
PENINSULA HEALTHCARE (UK) LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 MARCH 2025
- 12 -
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash (absorbed by)/generated from operations
28
(647,001)
502,341
Interest paid
(72,096)
(85,524)
Income taxes refunded/(paid)
260,430
(34,880)
Net cash (outflow)/inflow from operating activities
(458,667)
381,937
Investing activities
Purchase of property, plant and equipment
(30,165)
(246,197)
Net cash used in investing activities
(30,165)
(246,197)
Financing activities
Proceeds from issue of shares
150
25
Repayment of borrowings
1,249,850
Payment of lease liabilities
(223,640)
(83,151)
Net cash generated from/(used in) financing activities
1,026,360
(83,126)
Net increase in cash and cash equivalents
537,528
52,614
Cash and cash equivalents at beginning of year
118,943
66,329
Cash and cash equivalents at end of year
656,471
118,943
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
- 13 -
1
Accounting policies
Company information
Peninsula Healthcare (UK) Limited is a private company limited by shares incorporated in England and Wales. The registered office is . The company's principal activities and nature of its operations are disclosed in the directors' report.
The group consists of Peninsula Healthcare (UK) Limited and all of its subsidiaries.
1.1
Basis of preparation
The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted for use in the United Kingdom and with the requirements of the Companies Act 2006 applicable to companies reporting under IFRS, except as otherwise stated.
The financial statements are prepared in sterling, which is the functional currency of the group. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention, modified to include right-of-use assets and certain financial instruments at fair value. The principal accounting policies adopted are set out below.
The consolidated financial statements include comparative information for the year ended 31st March 2024. The group did not prepare audited consolidated financial statements in the prior year, therefore the comparative information presented in these financial statements are unaudited.
1.2
Business combinations
The cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill.
The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date.
Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date.
1.3
Basis of consolidation
The consolidated group financial statements consist of the financial statements of the parent company Peninsula Healthcare (UK) Limited together with all entities controlled by the parent company (its subsidiaries) and the group’s share of its interests in joint ventures and associates.
All financial statements are made up to 31 March 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.
All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
Subsidiaries are consolidated in the group’s financial statements from the date that control commences until the date that control ceases.
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 14 -
Entities in which the group holds an interest and which are jointly controlled by the group and one or more other venturers under a contractual arrangement are treated as joint ventures. Entities other than subsidiary undertakings or joint ventures, in which the group has a participating interest and over whose operating and financial policies the group exercises a significant influence, are treated as associates.
Investments in joint ventures and associates are carried in the group statement of financial position at cost plus post-acquisition changes in the group’s share of the net assets of the entity, less any impairment in value. The carrying values of investments in joint ventures and associates include acquired goodwill.
If the group’s share of losses in a joint venture or associate equals or exceeds its investment in the joint venture or associate, the group does not recognise further losses unless it has incurred obligations to do so or has made payments on behalf of the joint venture or associate.
Unrealised gains arising from transactions with joint ventures and associates are eliminated to the extent of the group’s interest in the entity.
1.4
Going concern
The group incurred a net loss of £288,793 (2024: £219,257) for the year ended 31 March 2025 and, as of that date, the group’s net current liabilities was £1,648,323 (2024: £2,836,619) and had net liabilities of ££1,174,392 (2024: £943,272)true
At the time of approving the financial statements, the directors have a reasonable expectation that the company will continue to be supported by its ultimate parent undertaking, Sheikh Holdings Group (Investments) Limited and other group companies to enable the company to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.5
Revenue
Turnover represents the invoiced value of fees, net of VAT where applicable, except in respect of service contracts where turnover is recognised when the right to consideration is obtained.
1.6
Goodwill
Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less impairment losses.
The gain on a bargain purchase is recognised in profit or loss in the period of the acquisition.
For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit. An impairment loss recognised for goodwill is not subsequently reversed.
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 15 -
1.7
Intangible assets other than goodwill
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.
Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives.
1.8
Property, plant and equipment
Property, plant and equipment are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Leasehold improvements
Straight line over lease term
Fixtures and fittings
20% reducing balance
Plant and equipment
20% reducing balance
Computers
20% reducing balance
Right of use asset
Over lease term
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the income statement.
1.9
Non-current investments
Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.
A subsidiary is an entity controlled by the parent company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
An associate is an entity, being neither a subsidiary nor a joint venture, in which the group holds a long-term interest and has significant influence. The group considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.
Entities in which the group has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.
1.10
Impairment of tangible and intangible assets
At each reporting end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the group estimates the recoverable amount of the cash-generating unit to which the asset belongs.
Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment annually, and whenever there is an indication that the asset may be impaired.
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 16 -
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
1.11
Inventories
Inventories are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition.
Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.
1.12
Cash and cash equivalents
Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.13
Financial assets
Financial assets are recognised in the group's statement of financial position when the group becomes party to the contractual provisions of the instrument. Financial assets are classified into specified categories, depending on the nature and purpose of the financial assets.
At initial recognition, financial assets classified as fair value through profit and loss are measured at fair value and any transaction costs are recognised in profit or loss. Financial assets not classified as fair value through profit and loss are initially measured at fair value plus transaction costs.
Financial assets at fair value through profit or loss
When any of the above-mentioned conditions for classification of financial assets is not met, a financial asset is classified as measured at fair value through profit or loss. Financial assets measured at fair value through profit or loss are recognized initially at fair value and any transaction costs are recognised in profit or loss when incurred. A gain or loss on a financial asset measured at fair value through profit or loss is recognised in profit or loss, and is included within finance income or finance costs in the statement of income for the reporting period in which it arises.
Financial assets held at amortised cost
Financial instruments are classified as financial assets measured at amortised cost where the objective is to hold these assets in order to collect contractual cash flows, and the contractual cash flows are solely payments of principal and interest. They arise principally from the provision of goods and services to customers (eg trade receivables). They are initially recognised at fair value plus transaction costs directly attributable to their acquisition or issue, and are subsequently carried at amortised cost using the effective interest rate method, less provision for impairment where necessary.
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 17 -
Financial assets at fair value through other comprehensive income
Debt instruments are classified as financial assets measured at fair value through other comprehensive income where the financial assets are held within the group’s business model whose objective is achieved by both collecting contractual cash flows and selling financial assets, and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.
A debt instrument measured at fair value through other comprehensive income is recognised initially at fair value plus transaction costs directly attributable to the asset. After initial recognition, each asset is measured at fair value, with changes in fair value included in other comprehensive income. Accumulated gains or losses recognised through other comprehensive income are directly transferred to profit or loss when the debt instrument is derecognised.
The parent company has made an irrevocable election to recognize changes in fair value of investments in equity instruments through other comprehensive income, not through profit or loss. A gain or loss from fair value changes will be shown in other comprehensive income and will not be reclassified subsequently to profit or loss. Equity instruments measured at fair value through other comprehensive income are recognized initially at fair value plus transaction cost directly attributable to the asset. After initial recognition, each asset is measured at fair value, with changes in fair value included in other comprehensive income. Accumulated gains or losses recognized through other comprehensive income are directly transferred to retained earnings when the equity instrument is derecognized or its fair value substantially decreased. Dividends are recognized as finance income in profit or loss.
Impairment of financial assets
Financial assets, other than those held at fair value, are assessed for indicators of impairment at each reporting end date.
Derecognition of financial assets
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership to another entity.
1.14
Financial liabilities
The group recognises financial debt when the group becomes a party to the contractual provisions of the instruments. Financial liabilities are classified as either 'financial liabilities at fair value through profit or loss' or 'other financial liabilities'.
Other financial liabilities
Other financial liabilities, including borrowings, trade payables and other short-term monetary liabilities, are initially measured at fair value net of transaction costs directly attributable to the issuance of the financial liability. They are subsequently measured at amortised cost using the effective interest method. For the purposes of each financial liability, interest expense includes initial transaction costs and any premium payable on redemption, as well as any interest or coupon payable while the liability is outstanding.
Derecognition of financial liabilities
Financial liabilities are derecognised when, and only when, the group’s obligations are discharged, cancelled, or they expire.
1.15
Equity instruments
Equity instruments issued by the parent company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer payable at the discretion of the company.
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 18 -
1.16
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax
Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences and deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the group has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.17
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as and expense as they fall due.
1.18
Leases
As lessee
At inception, the group assesses whether a contract is, or contains, a lease within the scope of IFRS 16. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Where a tangible asset is acquired through a lease, the group recognises a right-of-use asset and a lease liability at the lease commencement date. Right-of-use assets are included within property, plant and equipment, apart from those that meet the definition of investment property.
The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date plus any initial direct costs and an estimate of the cost of obligations to dismantle, remove, refurbish or restore the underlying asset and the site on which it is located, less any lease incentives received.
The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of other property, plant and equipment. The right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
1
Accounting policies
(Continued)
- 19 -
The lease liability is initially measured at the present value of the lease payments that are unpaid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the group's incremental borrowing rate. Lease payments included in the measurement of the lease liability comprise fixed payments, variable lease payments that depend on an index or a rate, amounts expected to be payable under a residual value guarantee, and the cost of any options that the group is reasonably certain to exercise, such as the exercise price under a purchase option, lease payments in an optional renewal period, or penalties for early termination of a lease.
The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in: future lease payments arising from a change in an index or rate; the group's estimate of the amount expected to be payable under a residual value guarantee; or the group's assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying amount of the right-of-use asset has been reduced to zero.
The group has elected not to recognise right-of-use assets and lease liabilities for short-term leases of machinery that have a lease term of 12 months or less, or for leases of low-value assets including IT equipment. The payments associated with these leases are recognised in profit or loss on a straight-line basis over the lease term.
2
Adoption of new and revised standards and changes in accounting policies
At the date of authorisation of these financial statements, certain new standards, amendments and interpretations to existing standards have been published by the IASB but are not yet effective and these have not been applied early by the company. Management anticipates that the following pronouncements relevant to the companies operation will be adopted in the companies accounting policies for the first period beginning after the effective date of the pronouncement, once adopted by the UK:
| | | | | Effective date per standard |
Amendments to IAS 12 deferred tax related to assets and liabilities arising from a single transaction | | | Recognition of deferred tax on transactions that, on initial recognition give rise to equal amounts of taxable and deductible temporary differences | | |
Amendments to IAS 12 international tax reform | | | Amendments provide a temporary exception to the requirements regarding deferred tax assets and liabilities related to pillar two income taxes | | |
Narrow scope amendments to IAS 1, practice statement 2 and IAS 8 | | | Improved accounting policy disclosures | | |
Amendments to IFRS 16, lease liability in a sale and leaseback | | | Amendments clarify how a seller-lessee subsequently measures sale and leaseback transactions that satisfy the requirements in IFRS 15 to be accounted for as a sale. | | |
Amendments to IAS 1, Non-current liabilities with covenants | | | Amendments clarify how conditions with which an entity must comply within twelve months after the reporting period affect the classification of a liability | | |
Disclosures: Supplier Finance Arrangements - | | | Amendments to IAS 7 and IFRS 7 | | |
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
2
Adoption of new and revised standards and changes in accounting policies
(Continued)
- 20 -
Issued IFRS not yet effective
At the date of authorisation of these financial statements, certain new standards, amendments and interpretations to existing standards have been published by the IASB but are not yet effective and these have not been applied early by the company. Management anticipates that the following pronouncements relevant to the companies operation will be adopted in the companies accounting policies for the first period beginning after the effective date of the pronouncement:
| | | | | Effective date per standard |
Annual Improvements to IFRS Standards 2018–2020 Volume 11 | | | Amendments to IFRS 1, IFRS 7, IFRS9, and IFRS10 | | |
Subsidiaries without Public Accountability: Disclosures | | | IFRS 18 and 19 specifies reduced disclosure requirements in financial statements | | |
Classification and Measurement of financial instruments | | | Amendments to IFRS 9 and IFRS 7 for the Classification and Measurement of Financial Instruments. | | |
| | | | | |
Contracts Referencing Nature-dependent Electricity – | | | Amendments to IFRS 9 and IFRS 7 | | |
IFRS 18 – Presentation and Disclosure in Financial Statements | | | | | |
Sale or Contribution of Assets between an Investor and its Associate or Joint Venture - Amendments to | | | | | |
Note (a): In December 2015, the IASB postponed the effective date of this amendment indefinitely pending the outcome of its research project on the equity method of accounting.
The Directors expect that the adoption of the standards listed above will not have a material impact on the financial information of the company in future reporting periods.
3
Revenue
2025
2024
£
£
Revenue analysed by class of business
Dental income
7,401,072
7,890,943
2025
2024
£
£
Revenue analysed by geographical market
UK
7,401,072
7,890,943
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 21 -
4
Operating profit
2025
2024
Operating loss for the year is stated after charging/(crediting):
£
£
Depreciation of property, plant and equipment
424,367
456,350
Loss on disposal of property, plant and equipment
10,154
-
Amortisation of intangible assets
75,717
22,715
Cost of inventories recognised as an expense
4,346,316
4,531,229
5
Auditor's remuneration
2025
2024
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the group and company
32,250
10,705
Audit of the financial statements of the company's subsidiaries
-
15,112
32,250
25,817
6
Employees
The average monthly number of persons (including directors) employed by the group during the year was:
2025
2024
Number
Number
Management
35
35
Other
17
9
Total
52
44
Their aggregate remuneration comprised:
2025
2024
£
£
Wages and salaries
1,282,363
1,363,498
Social security costs
82,115
81,774
Pension costs
7,719
10,049
1,372,197
1,455,321
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 22 -
7
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
171,320
153,773
Company pension contributions to defined contribution schemes
220
881
171,540
154,654
8
Finance costs
2025
2024
£
£
Interest on lease liabilities
71,834
82,572
Other interest payable
262
2,952
Total interest expense
72,096
85,524
9
Income tax expense
2025
2024
£
£
Current tax
Adjustments in respect of prior periods
4,347
Other tax reliefs
(260,169)
-
Total UK current tax
(255,822)
Deferred tax
Origination and reversal of temporary differences
(32,971)
6,632
Total tax charge/(credit)
(288,793)
6,632
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
9
Income tax expense
(Continued)
- 23 -
The charge for the year can be reconciled to the loss per the income statement as follows:
2025
2024
£
£
Loss before taxation
(520,063)
(212,625)
Expected tax credit based on a corporation tax rate of 25.00% (2024: 25.00%)
(130,016)
(53,156)
Effect of expenses not deductible in determining taxable profit
95,701
81,156
Adjustment in respect of prior years
4,347
-
Group relief
38,932
28,025
Permanent capital allowances in excess of depreciation
(4,617)
(56,025)
Deferred tax movement
(32,971)
6,632
28,528
-
Group tax relief payment/(credit)
(288,697)
-
Taxation (credit)/charge for the year
(288,793)
6,632
10
Intangible assets
Goodwill
Software
Total
£
£
£
Cost
At 1 April 2023
570,412
227,152
797,564
At 31 March 2024
570,412
227,152
797,564
At 31 March 2025
570,412
227,152
797,564
Amortisation and impairment
At 1 April 2023
-
-
-
Charge for the year
-
22,715
22,715
At 31 March 2024
-
22,715
22,715
Charge for the year
75,717
75,717
At 31 March 2025
98,432
98,432
Carrying amount
At 31 March 2025
570,412
128,720
699,132
At 31 March 2024
570,412
204,437
774,849
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 24 -
11
Property, plant and equipment
Leasehold improvements
Plant and equipment
Fixtures and fittings
Computers
Right of use asset
Total
£
£
£
£
£
£
Cost
At 1 April 2023
951,265
1,322,203
418,349
159,703
2,091,834
4,943,354
Additions
71,634
72,628
2,772
99,163
246,197
At 31 March 2024
1,022,899
1,394,831
421,121
258,866
2,091,834
5,189,551
Additions
4,825
25,340
30,165
Disposals
(13,200)
(3,576)
(16,776)
At 31 March 2025
1,022,899
1,386,456
442,885
258,866
2,091,834
5,202,940
Accumulated depreciation and impairment
At 1 April 2023
368,258
884,064
184,375
75,609
729,054
2,241,360
Charge for the year
78,440
116,723
47,530
23,009
190,648
456,350
At 31 March 2024
446,698
1,000,787
231,905
98,618
919,702
2,697,710
Charge for the year
81,548
96,749
37,307
18,115
190,648
424,367
Eliminated on disposal
(5,726)
(896)
(6,622)
At 31 March 2025
528,246
1,091,810
268,316
116,733
1,110,350
3,115,455
Carrying amount
At 31 March 2025
494,653
294,646
174,569
142,133
981,484
2,087,485
At 31 March 2024
576,201
394,044
189,216
160,248
1,172,132
2,491,841
The NBV of assets held under hire purchase arrangements at the year end date was £124,258 (2024: £155,322).
12
Subsidiaries
Details of the company's subsidiaries at 31 March 2025 are as follows:
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
RUH Dental (Fleet Steet)
Parkview House Ground Floor, 82 Oxford Road, Uxbridge, United Kingdom, UB8 1UX
Ordinary
75.00
RUH Dental (Notting Hill Gate)
Parkview House Ground Floor, 82 Oxford Road, Uxbridge, United Kingdom, UB8 1UX
Ordinary
95.00
RUH Dental (Manchester)
Parkview House Ground Floor, 82 Oxford Road, Uxbridge, United Kingdom, UB8 1UX
Ordinary
75.00
RUH Dental Training Academy
Parkview House Ground Floor, 82 Oxford Road, Uxbridge, United Kingdom, UB8 1UX
Ordinary
100.00
RUH Lifestyle
Parkview House Ground Floor, 82 Oxford Road, Uxbridge, United Kingdom, UB8 1UX
Ordinary
100.00
RUH (KBH)
Parkview House Ground Floor, 82 Oxford Road, Uxbridge, United Kingdom, UB8 1UX
Ordinary
100.00
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 25 -
13
Inventories
2025
2024
£
£
Raw materials
32,143
91,638
14
Trade and other receivables
2025
2024
£
£
VAT recoverable
1,844
8,635
Other receivables
225,370
100,169
Prepayments
221,288
298,787
448,502
407,591
15
Trade receivables - credit risk
Fair value of trade receivables
The directors consider that the carrying amount of trade and other receivables differs from fair value as follows:
Carrying value
Fair value
2025
2024
2025
2024
£
£
£
£
Other debtors
225,370
100,169
-
Prepayments
221,288
298,787
-
446,658
398,956
No significant receivable balances are impaired at the reporting end date.
16
Borrowings
Non-current
2025
2024
£
£
Borrowings held at amortised cost:
Loans from related parties
1,249,850
-
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 26 -
17
Trade and other payables
Current
Non-current
2025
2024
2025
2024
£
£
£
£
Trade payables
736,268
701,423
Amounts owed to fellow group undertakings
755,188
1,426,929
-
63,769
Accruals
700,630
528,619
Social security and other taxation
32,675
120,481
Other payables
340,393
451,789
-
-
2,565,154
3,229,241
-
63,769
18
Lease liabilities
2025
2024
Net amounts due
£
£
Within one year
215,676
225,550
After more than one year
931,624
1,145,390
1,147,300
1,370,940
2025
2024
Maturity analysis of future lease payments
£
£
Within one year
215,677
225,549
In two to five years
888,766
887,719
In over five years
42,857
257,672
Total undiscounted liabilities
1,147,300
1,370,940
Other leasing information is included in note 23.
19
Deferred taxation
Liabilities
2025
2024
£
£
Deferred tax balances
131,212
164,184
The following are the major deferred tax liabilities and assets recognised by the group and movements thereon during the current and prior reporting period.
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
19
Deferred taxation
(Continued)
- 27 -
ACAs
£
Liability at 1 April 2023
157,553
Deferred tax movements in prior year
Charge/(credit) to profit or loss
6,631
Liability at 1 April 2024
164,184
Deferred tax movements in current year
Charge/(credit) to profit or loss
(32,972)
Liability at 31 March 2025
131,212
20
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
7,719
10,049
The group operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the group in an independently administered fund.
21
Share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary of £1 each
1,000
101
1,000
101
22
Share premium account
2025
2024
£
£
At the beginning of the year
999,999
999,999
Share issue expenses
(749)
At the end of the year
999,250
999,999
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 28 -
23
Other leasing information
As lessee
2025
2024
Land and buildings
£
£
Within one year
180,565
171,678
Between two and five years
814,547
780,296
In over five years
42,857
257,672
1,037,969
2,419,293
2025
2024
Operating leases apart from land and buildings
£
£
Within one year
35,112
53,871
Between two and five years
74,219
107,423
109,331
161,294
24
Capital risk management
The group is not subject to any externally imposed capital requirements.
PENINSULA HEALTHCARE (UK) LIMITED
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 29 -
25
Related party transactions
At the balance sheet date, the group owed £1,015,359 (2024: £1,490,698) to ultimate parent company Sheikh Holdings Group (Investments) Limited.
26
Controlling party
The company's immediate parent undertaking is Locksbridge Capital Limited and its ultimate parent undertaking is Sheikh Holdings Group (Investments) Limited.
The following are the parents of the largest and smallest groups in which this company's results are consolidated:
Largest group
Sheikh Holdings Group (Investments) Limited
Smallest group
Sheikh Holdings Group (Investments) Limited
27
Exemption from audit by parent guarantee
The company being the majority shareholder of its subsidiaries has decided to take the exemption from audit of a number of subsidiaries for the year ended 31 March 2025 under Sections 479A and 479C of the Companies Act 2006 and the company will provide a guarantee for all the liabilities of those entities as at 31 March 2025.
RUH Dental (Fleet Street) Limited
RUH Dental (Manchester) Limited
RUH Dental (Notting Hill Gate) Limited
RUH Dental Training Academy Limited
RUH Lifestyle Limited
RUH (KBH) Limited
28
Cash (absorbed by)/generated from group operations
2025
2024
£
£
Loss for the year before taxation
(520,063)
(212,625)
Adjustments for:
Finance costs
72,096
85,524
Loss on disposal of property, plant and equipment
10,154
-
Amortisation and impairment of intangible assets
75,717
22,715
Depreciation and impairment of property, plant and equipment
424,367
456,350
Movements in working capital:
Decrease in inventories
59,495
18,859
(Increase)/decrease in trade and other receivables
(40,911)
152,200
Decrease in trade and other payables
(727,856)
(20,682)
Cash (absorbed by)/generated from operations
(647,001)
502,341
PENINSULA HEALTHCARE (UK) LIMITED
COMPANY STATEMENT OF FINANCIAL POSITION
AS AT
31 MARCH 2025
31 March 2025
- 30 -
2025
2024
Notes
£
£
Non-current assets
Intangible assets
30
128,720
204,437
Property, plant and equipment
31
-
10,154
Investments
32
779,203
779,203
907,923
993,794
Current assets
Trade and other receivables
33
832,491
17,681
Current liabilities
Trade and other payables
35
105,018
572,733
Lease liabilities
36
1,080
5,760
106,098
578,493
Net current assets/(liabilities)
726,393
(560,812)
Non-current liabilities
Borrowings
34
1,249,850
-
Net assets
384,466
432,982
Equity
Called up share capital
37
1,000
101
Share premium account
999,250
999,999
Retained earnings
(615,784)
(567,118)
Total equity
384,466
432,982
As permitted by trues408 Companies Act 2006, the company has not presented its own income statement and related notes. The company’s loss for the year was £48,666 (2024 - £34,061 loss).
The financial statements were approved by the board of directors and authorised for issue on 20 December 2025 and are signed on its behalf by:
20 December 2025
Dr Z Sheikh
Director
Company registration number 09082491 (England and Wales)
PENINSULA HEALTHCARE (UK) LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2025
- 31 -
Share capital
Share premium account
Retained earnings
Total
Notes
£
£
£
£
Balance at 1 April 2023
101
999,999
(533,057)
467,043
Year ended 31 March 2024:
Loss and total comprehensive income
-
-
(34,061)
(34,061)
Balance at 31 March 2024
101
999,999
(567,118)
432,982
Year ended 31 March 2025:
Loss and total comprehensive income
-
-
(48,666)
(48,666)
Transactions with owners:
Issue of share capital
37
150
(749)
-
(599)
Bonus issue
37
749
-
-
749
Balance at 31 March 2025
1,000
999,250
(615,784)
384,466
PENINSULA HEALTHCARE (UK) LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 32 -
29
Employees - company
The average monthly number of persons (including directors) employed by the company during the year was:
2025
2024
Number
Number
Management
3
3
Other
8
9
Total
11
12
Their aggregate remuneration comprised:
2025
2024
£
£
Wages and salaries
516,506
577,848
Social security costs
58,168
57,823
Pension costs
4,043
6,434
578,717
642,105
30
Intangible assets - company
Software
£
Cost
At 1 April 2023
227,152
At 31 March 2024
227,152
At 31 March 2025
227,152
Amortisation and impairment
Charge for the year
22,715
At 31 March 2024
22,715
Charge for the year
75,717
At 31 March 2025
98,432
Carrying amount
At 31 March 2025
128,720
At 31 March 2024
204,437
PENINSULA HEALTHCARE (UK) LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 33 -
31
Property, plant and equipment - company
Plant and equipment
Fixtures and fittings
Total
£
£
£
Cost
At 1 April 2023
13,200
2,971
16,171
Additions
-
605
605
At 31 March 2024
13,200
3,576
16,776
Disposals
(13,200)
(3,576)
(16,776)
At 31 March 2025
-
-
-
Accumulated depreciation and impairment
At 1 April 2023
3,234
-
3,234
Charge for the year
2,492
896
3,388
At 31 March 2024
5,726
896
6,622
Eliminated on disposal
(5,726)
(896)
(6,622)
At 31 March 2025
-
-
-
Carrying amount
At 31 March 2025
-
-
-
At 31 March 2024
7,474
2,680
10,154
32
Investments - company
Current
Non-current
2025
2024
2025
2024
£
£
£
£
Investments in joint ventures
779,203
779,203
The company has not designated any financial assets that are not classified as held for trading as financial assets at fair value through profit or loss.
Investment in subsidiary undertakings
Details of the company's principal operating subsidiaries are included in note 10.
PENINSULA HEALTHCARE (UK) LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025
- 34 -
33
Trade and other receivables - company
2025
2024
£
£
VAT recoverable
-
6,791
Amounts owed by fellow group undertakings
821,892
Other receivables
-
4,299
Prepayments
10,599
6,591
832,491
17,681
Debtors disclosed above are classified as loans and receivables and are therefore measured at amortised cost.
34
Borrowings - company
Non-current
2025
2024
£
£
Borrowings held at amortised cost:
Loans from related parties
1,249,850
-
35
Trade and other payables - company
2025
2024
£
£
Trade payables
23,598
26,206
Amounts owed to fellow group undertakings
-
459,028
Accruals
65,228
3,700
Social security and other taxation
16,192
83,799
105,018
572,733
36
Lease liabilities
2025
2024
Net amounts due
£
£
Within one year
1,080
5,760
After more than one year
37
Share capital - company
Refer to note 21 of the group financial statements.
2025-03-312024-04-01falseCCH SoftwareCCH Accounts Production 2025.300Dr Z SheikhDr R Mahmoodfalse090824912024-04-012025-03-3109082491bus:Consolidated2024-04-012025-03-3109082491bus:Director1bus:Consolidated2024-04-012025-03-3109082491bus:Director2bus:Consolidated2024-04-012025-03-3109082491bus:Director12024-04-012025-03-3109082491bus:Director22024-04-012025-03-3109082491bus:Consolidated2025-03-31090824912025-03-3109082491core:ContinuingOperationsbus:Consolidated2024-04-012025-03-3109082491bus:Consolidated2023-04-012024-03-3109082491core:ContinuingOperationsbus:Consolidated2023-04-012024-03-3109082491core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-04-012025-03-3109082491core:RetainedEarningsAccumulatedLossesbus:Consolidated2023-04-012024-03-3109082491core:Goodwillbus:Consolidated2025-03-3109082491core:Goodwillbus:Consolidated2024-03-3109082491core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2025-03-3109082491core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2024-03-31090824912024-03-3109082491bus:Consolidated2024-03-3109082491bus:Consolidated2024-03-3109082491core:CurrentFinancialInstrumentsbus:Consolidated2025-03-3109082491core:CurrentFinancialInstruments2025-03-3109082491core:ShareCapitalbus:Consolidated2025-03-3109082491core:ShareCapitalbus:Consolidated2024-03-3109082491core:SharePremiumbus:Consolidated2025-03-3109082491core:SharePremiumbus:Consolidated2024-03-3109082491core:RetainedEarningsAccumulatedLosses2025-03-3109082491core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-03-3109082491core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterestsbus:Consolidated2025-03-3109082491core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterestsbus:Consolidated2024-03-3109082491core:Non-controllingInterests2025-03-3109082491core:Non-controllingInterests2024-03-3109082491core:RetainedEarningsAccumulatedLossesbus:Consolidated2023-03-3109082491core:ShareCapitalbus:Consolidated2024-04-012025-03-3109082491core:SharePremiumbus:Consolidated2024-04-012025-03-3109082491core:Goodwillbus:Consolidated2024-04-012025-03-3109082491core:IntangibleAssetsOtherThanGoodwillbus:Consolidated2024-04-012025-03-31090824912023-04-012024-03-3109082491core:UKTaxbus:Consolidated2024-04-012025-03-3109082491core:UKTaxbus:Consolidated2023-04-012024-03-3109082491core:Goodwillbus:Consolidated2023-03-3109082491core:ComputerSoftwarebus:Consolidated2023-03-3109082491bus:Consolidated2023-03-3109082491core:ComputerSoftwarebus:Consolidated2024-03-3109082491core:ComputerSoftwarebus:Consolidated2025-03-3109082491core:ComputerSoftwarebus:Consolidated2024-04-012025-03-3109082491core:LeaseholdImprovementscore:LeasedAssetsHeldAsLesseebus:Consolidated2023-03-3109082491core:PlantMachinerybus:Consolidated2023-03-3109082491core:FurnitureFittingsbus:Consolidated2023-03-3109082491core:ComputerEquipmentbus:Consolidated2023-03-3109082491core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2023-03-3109082491core:LeaseholdImprovementscore:LeasedAssetsHeldAsLesseebus:Consolidated2024-03-3109082491core:PlantMachinerybus:Consolidated2024-03-3109082491core:FurnitureFittingsbus:Consolidated2024-03-3109082491core:ComputerEquipmentbus:Consolidated2024-03-3109082491core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2024-03-3109082491core:LeaseholdImprovementscore:LeasedAssetsHeldAsLesseebus:Consolidated2025-03-3109082491core:PlantMachinerybus:Consolidated2025-03-3109082491core:FurnitureFittingsbus:Consolidated2025-03-3109082491core:ComputerEquipmentbus:Consolidated2025-03-3109082491core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2025-03-3109082491core:LeaseholdImprovementscore:LeasedAssetsHeldAsLesseebus:Consolidated2023-04-012024-03-3109082491core:PlantMachinerybus:Consolidated2023-04-012024-03-3109082491core:FurnitureFittingsbus:Consolidated2023-04-012024-03-3109082491core:ComputerEquipmentbus:Consolidated2023-04-012024-03-3109082491core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2023-04-012024-03-3109082491core:LeaseholdImprovementscore:LeasedAssetsHeldAsLesseebus:Consolidated2024-04-012025-03-3109082491core:PlantMachinerybus:Consolidated2024-04-012025-03-3109082491core:FurnitureFittingsbus:Consolidated2024-04-012025-03-3109082491core:ComputerEquipmentbus:Consolidated2024-04-012025-03-3109082491core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipmentbus:Consolidated2024-04-012025-03-3109082491core:FurnitureFittingsbus:Consolidated2024-03-31090824912023-03-3109082491core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2024-03-31090824912024-03-3109082491core:LandBuildingscore:LeasedAssetsHeldAsLesseebus:Consolidated2024-04-012025-03-3109082491core:Subsidiary1bus:Consolidated2024-04-012025-03-3109082491core:Subsidiary2bus:Consolidated2024-04-012025-03-3109082491core:Subsidiary3bus:Consolidated2024-04-012025-03-3109082491core:Subsidiary4bus:Consolidated2024-04-012025-03-3109082491core:Subsidiary5bus:Consolidated2024-04-012025-03-3109082491core:Subsidiary6bus:Consolidated2024-04-012025-03-3109082491core:Subsidiary1bus:Consolidated12024-04-012025-03-3109082491core:Subsidiary2bus:Consolidated22024-04-012025-03-3109082491core:Subsidiary3bus:Consolidated32024-04-012025-03-3109082491core:Subsidiary4bus:Consolidated42024-04-012025-03-3109082491core:Subsidiary5bus:Consolidated52024-04-012025-03-3109082491core:Subsidiary6bus:Consolidated62024-04-012025-03-3109082491core:CurrentFinancialInstrumentsbus:Consolidated2024-03-3109082491core:FairValue2025-03-3109082491core:CurrentFinancialInstruments2024-03-3109082491core:FairValuebus:Consolidated2025-03-3109082491core:FairValuebus:Consolidated2024-03-3109082491core:Non-currentFinancialInstrumentsbus:Consolidated2025-03-3109082491core:Non-currentFinancialInstrumentsbus:Consolidated2024-03-3109082491core:Non-currentFinancialInstruments2025-03-3109082491core:Non-currentFinancialInstruments2024-03-3109082491core:AcceleratedTaxDepreciationDeferredTax2024-03-3109082491core:AcceleratedTaxDepreciationDeferredTax2025-03-3109082491bus:CompanyLimitedByGuaranteebus:Consolidated2024-04-012025-03-3109082491bus:Auditedbus:Consolidated2024-04-012025-03-3109082491bus:FullIFRS2024-04-012025-03-3109082491bus:FullAccountsbus:Consolidated2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP